Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
Adult was given a pediatric dose of Hepatitis B; Adult was given a pediatric dose of Hepatitis B; This non-serious case was reported by a other health professional via other manufacturer and described the occurrence of underdose in a adult patient who received HBV (Engerix B pediatric) for prophylaxis. On an unknown date, the patient received Engerix B pediatric. On an unknown date, an unknown time after receiving Engerix B pediatric, the patient experienced underdose (Verbatim: Adult was given a pediatric dose of Hepatitis B) and adult use of a child product (Verbatim: Adult was given a pediatric dose of Hepatitis B). The outcome of the underdose and adult use of a child product were not applicable. Additional Information: GSK receipt date: 28-MAR-2025 The healthcare professional called to report that an adult was given a pediatric dose of Hepatitis B, which led to underdose and adult use of a child product. Upon speaking with the reporter, identified it was a GlaxoSmithKline vaccine, Engerix. Caller did not provide additional details and ended call to make the call to the other manufacturer. No adverse side effects were reported. No additional information available at this time. No additional adverse event/no product quality complaint (PQC) were reported.